ARTICLE | Company News
Arena other research news
January 24, 2000 8:00 AM UTC
Arena received a $106,000 Phase I SBIR grant from the National Institute of Mental Health to develop its serotonin 5HT2A receptor inverse agonists as atypical, antipsychotic agents using its CART tech...